NCT06180473Completed
Evaluation of Tolerability, Efficacy and Adherence to Treatment With Wynzora Cream
Evaluation of Tolerability, Efficacy and Adherence to Treatment With Wynzora Cream in Patients With Psoriasis Previously Treated With Enstilar Foam.
Source: ClinicalTrials.gov · Last updated 2 Sept 2025
Brief summary (registry, in English)
The primary objective is to assess with the PPQ questionnaire the patient preference for Wynzora compared with therapy carried out previously with Enstilar spray foam. Secondary objectives Assess satisfaction with the treatment. Assess adherence to therapy. Evaluate the impact of various clinical and demographic factors on treatment adherence. Evaluate the efficacy of Wynzora cream therapy.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 30 (actual)
- First submitted
- 12 Dec 2023
- Start date
- 1 Jan 2024
- Primary completion date
- 31 Mar 2024
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Diseases
- Psoriasis
- NCT number
- NCT06180473
What you commit to
- Study type: Observational
- Participants enrolled: 30
- From 1 Jan 2024 to the primary completion date, 31 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who are taking concomitant systemic therapies for psoriasis, such as. cyclosporine, methotrexate, acitretin, phototherapy or biologic therapies.
- Patients with disabilities or other motor problems that could complicate self-medication.
Other
- Patients with palmoplantar, inverse, erythrodermic, guttate, and scalp psoriasis.
- Women who are pregnant or planning to become pregnant.
Who the study is looking for
- Patients older than 18 years of age, of either sex;
- Patients diagnosed with mild-to-moderate psoriasis (PASI and BSA \<10) requiring monotherapy topical with Wynzora;
- Patients who have stopped treatment with Enstilar foam for any reason for at least 30 days; and
- Patients whose medical records are accessible and record all demographic parameters, anthropometric and clinical parameters during the treatment period
- Signature of written informed consent;
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Policlinico Agostino Gemelli Coordinator of this site? Confirm its status | Rome | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.